SCHEMBL377914

SCHEMBL377914

CC(C)(C)OC(=O)N1CCC(Nc2cccc(F)c2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
NPC1 O15118 1/20 0.61
MAPT P10636 1/20 0.61
MAPK1 P28482 1/20 0.61
HTT P42858 1/20 0.61
RAB9A P51151 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
KDM4E B2RXH2 2/20 0.55
GPR119 Q8TDV5 3/20 0.53
LMNA P02545 1/20 0.52
MLNR O43193 3/20 0.52
HPGDS O60760 1/20 0.52
CCNT1 O60563 1/20 0.51
TP53 P04637 1/20 0.49
EPHX2 P34913 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPN6 P29350 1/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13159414 0.87 ALDH1A1 (0.63) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL4308625 0.87 GPR119 (0.64) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL5001323 0.86 EPHX2 (0.68) ALDH1A1NPC1MAPTRAB9AGPR119
SCHEMBL1704655 0.86 ALDH1A1 (0.60) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL32665106 0.86 ALDH1A1 (0.62) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL30056476 0.86 ALDH1A1 (0.62) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL27167162 0.86 ALDH1A1 (0.62) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL22587834 0.86 ALDH1A1 (0.62) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL1704497 0.85 ALDH1A1 (0.68) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL377801 0.85 ALDH1A1 (0.75) ALDH1A1NPC1MAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP claimed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US claimed
US-9902712-B2 Nitrogenous heterocyclic derivatives and their application in drugs SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-02-27 US disclosed
EP-3083584-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF TISSUE FIBROSIS SUNSHINE LAKE PHARMA CO LTD (CN) 2018-02-21 EP disclosed
CN-104725356-B Nitrogen heterocyclic derivatives and application thereof in medicine 广东东阳光药业有限公司 2017-02-22 CN disclosed
US-20160355501-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-12-08 US disclosed
US-20130317041-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-11-28 US disclosed
US-8536182-B2 Benzylpiperazine derivatives and their medical use GLAXO GROUP LIMITED (GB) 2013-09-17 US disclosed
EP-1907374-B1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders GLAXO GROUP LTD (GB) 2012-08-22 EP disclosed
US-8236953-B2 Process for preparing piper azine derivatives GLAXO GROUP LIMITED (GB) 2012-08-07 US disclosed
US-8236953-B2 Process for preparing piper azine derivatives GLAXO GROUP LIMITED (GB) 2012-08-07 US disclosed
EP-1907374-A2 COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-09 EP disclosed
WO-2007144400-A1 BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2007-12-21 WO disclosed
WO-2007144400-A1 BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2007-12-21 WO disclosed
WO-2007012479-A2 BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2007-02-01 WO disclosed
EP-1693061-A1 Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases UCB, S.A. (BE) 2006-08-23 EP disclosed
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP disclosed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US disclosed
EP-1556045-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2005-07-27 EP disclosed
WO-2004030668-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments PNMT, HTR5A, HTR4 ALDH1A1 1143/4885NPC1 3494/4885MAPT 549/4885
US-20130317041-A1 COMPOUNDS GPR68, GPR88, GPR35 ALDH1A1 1802/4885NPC1 615/4885MAPT 4143/4885
US-20160355501-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS TNNC1, IAPP, TNNI3 ALDH1A1 1615/4885NPC1 3412/4885MAPT 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.